Shares of Hims & Hers Health Inc. rallied after hours on Monday after the wellness platform bumped its full-year sales ...

Hims & Hers Health, Inc. (NYSE:HIMS) has been under pressure this week, with shares declining over 10%, following Eli Lilly's ...

Hims & Hers Health (HIMS) stock gains after its Q3 2024 results as company plans to launch a generic version of Novo ...

HIMS boasts high gross margins (~80%) with no R&D risk, capitalizing on the shift away from traditional pharmacies to ...

Hims & Hers Health (HIMS) shares jumped in extended trading after the company reported better than expected third quarter ...

The millennial-skewed telehealth platform Hims & Hers (HIMS) announced Monday that it will start offering customers a generic version of liraglutide, an older GLP-1 weight loss drug, next year. The ...

Compounded GLP-1s are essentially copies of popular weight loss medications made by manufacturers such as Novo Nordisk and Eli Lilly. Hims & Hers CEO Andrew Dudum said during the company's third ...

Piper Sandler analyst Korinne Wolfmeyer raised the firm’s price target on Hims & Hers to $21 from $18 and keeps a Neutral rating on ...

Hims & Hers currently offers compounded GLP-1 weight-loss injections at $199 per month and weight management oral medication ...

TD Cowen analyst Jonna Kim maintained a Buy rating on Hims & Hers Health (HIMS – Research Report) today and set a price target of ...

Hims & Hers (HIMS) stock price remained on edge even after the fast-growing telehealth company published strong financial ...

Q3 2024 Earnings Call Transcript November 4, 2024 Operator: Ladies and gentlemen, thank you for standing by. My name is Krista, and I will be your conference operator today. At this time, I would like ...